Russian range of medicines continues to decline
The range medicines available in Russian pharmacies is steadily declining, which is mainly due to tough economic environment in the country, caused by Western sanctions and the existing problems with logistics, reports The Pharma Letter’s local correspondent.
In recent months the range of drugs in the Russian pharmaceutical retail chain has decreased by almost 2,000 items, while among the major reasons of this was the decline of imports and the reluctance of drugmakers to produce and supply to Russia unprofitable for them drugs.
According to analysts at the Russian DSM Group agency, in 2022 the supply in pharmaceutical retail decreased by almost 10%, or about 2,000 items and amounted to 21,600 units.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze